FDA-cleared profile

Morph

BeauBrain Healthcare, Inc. · MRI · FDA-cleared (510(k))

Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.

Clinical role
Automatic brain-structure labeling, visualization, volumetric quantification, and reference comparison.
Images and patients
MRI · Brain
Key limitation
Keep in mind: Morph is adjunctive and not the sole basis for clinical decisions. Results depend on standardized T1 acquisition, segmentable structures, reference data, and professional review.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: Standardized DICOM T1 brain MR images.
  • Who uses it?Intended users: Radiologists, neurologists, neuroradiologists, and other trained medical professionals.
  • What does the software produce?Output: Quantitative brain-structure assessments, reference comparisons, reports, and visualizations for clinician review.
  • What is its most important limitation?Key limitation: Morph is adjunctive and not the sole basis for clinical decisions. Results depend on standardized T1 acquisition, segmentable structures, reference data, and professional review.

Clinical takeaway. Clinical role: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports standalone segmentation testing on 64 independent 3D T1-weighted MRI scans, with a reference standard of manual segmentation by two U.S. board-certified neuroradiologists. Against a predefined mean DSC acceptance criterion of 0.70, Dice coefficients were >0.97 in the lateral ventricles and approximately 0.71 in occipital CSF regions, and the overall mean DSC exceeded 0.85. Volumetric agreement with expert reference measurements was within predefined clinically acceptable 95% LoA ranges. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Automatic brain-structure labeling, visualization, volumetric quantification, and reference comparison.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Standardized DICOM T1 brain MR images.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Quantitative brain-structure assessments, reference comparisons, reports, and visualizations for clinician review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Brain-MR interpretation workflows in hospitals and qualified imaging facilities.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Radiologists, neurologists, neuroradiologists, and other trained medical professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Morph is adjunctive and not the sole basis for clinical decisions. Results depend on standardized T1 acquisition, segmentable structures, reference data, and professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports standalone segmentation testing on 64 independent 3D T1-weighted MRI scans, with a reference standard of manual segmentation by two U.S. board-certified neuroradiologists. Against a predefined mean DSC acceptance criterion of 0.70, Dice coefficients were >0.97 in the lateral ventricles and approximately 0.71 in occipital CSF regions, and the overall mean DSC exceeded 0.85. Volumetric agreement with expert reference measurements was within predefined clinically acceptable 95% LoA ranges. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Standalone performance testing was conducted using a validation dataset consisting of 64 independent 3D T1-weighted MRI scans." … "The reference standard for segmentation accuracy evaluation was established through manual segmentation of 64 MRI scans by two U.S. board-certified neuroradiologists". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports standalone segmentation testing on 64 independent 3D T1-weighted MRI scans, with a reference standard of manual segmentation by two U.S. board-certified neuroradiologists. Against a predefined mean DSC acceptance criterion of 0.70, Dice coefficients were >0.97 in the lateral ventricles and approximately 0.71 in occipital CSF regions, and the overall mean DSC exceeded 0.85. Volumetric agreement with expert reference measurements was within predefined clinically acceptable 95% LoA ranges. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Standalone performance testing was conducted using a validation dataset consisting of 64 independent 3D T1-weighted MRI scans." … "The reference standard for segmentation accuracy evaluation was established through manual segmentation of 64 MRI scans by two U.S. board-certified neuroradiologists". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No single product-level sensitivity value was promoted because the reviewed FDA material is workflow, module, sequence, or population specific.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No single product-level specificity value was promoted because the reviewed FDA material is workflow, module, sequence, or population specific.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K260032 FDA evidence package for Morph

  • DesignFDA 510(k) verification and validation evidence described in the exact submission
  • PopulationBrain
  • Scopeexact submission
  • Tested versionMorph
  • IndependenceSponsor or vendor study

K260032

Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no candidate record for K260032; no exact native submission identifier match was found.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed CMS material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Standardized DICOM T1 brain MR images.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K260032: Morph

  2. Routing

    Source context, not route validation: The FDA package describes standardized DICOM T1 input and web-client results; exact PACS routing, report return, and local interfaces require testing.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K260032: Morph

  3. AI processing

    Source context, not route validation: The FDA package describes a web client with either cloud AWS or on-premises server deployment; the installed mode, hosting contract, security boundary, and local qualification remain unverified.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K260032: Morph

  4. Returned objects

    Source context, not route validation: Quantitative brain-structure assessments, reference comparisons, reports, and visualizations for clinician review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K260032: Morph

  5. Viewer/worklist/report

    Unresolved route: Quantitative brain-structure assessments, reference comparisons, reports, and visualizations for clinician review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K260032: Morph

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA package describes a web client with either cloud AWS or on-premises server deployment; the installed mode, hosting contract, security boundary, and local qualification remain unverified.
  • Exact FDA submission
  • Checked 2026-09-04
Integration
The FDA package describes standardized DICOM T1 input and web-client results; exact PACS routing, report return, and local interfaces require testing.
  • Exact FDA submission
  • Checked 2026-09-04
Training
Only radiologists, neurologists, neuroradiologists, and other trained medical professionals. should operate or interpret this product. Local onboarding must cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K260032 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Morph is adjunctive and not the sole basis for clinical decisions. Results depend on standardized T1 acquisition, segmentable structures, reference data, and professional review.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map the installed product, build, options, population, anatomy, inputs, outputs, and enabled functions to K260032 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The FDA package describes a web client with either cloud AWS or on-premises server deployment; the installed mode, hosting contract, security boundary, and local qualification remain unverified.

exact submission · checked 2026-09-04

FDA-described deployment details do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA package describes standardized DICOM T1 input and web-client results; exact PACS routing, report return, and local interfaces require testing.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Morph is adjunctive and not the sole basis for clinical decisions. Results depend on standardized T1 acquisition, segmentable structures, reference data, and professional review.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price or product-specific reimbursement was established in the reviewed public material.

Lifecycle monitoring

Monitor K260032 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Morph is adjunctive and not the sole basis for clinical decisions. Results depend on standardized T1 acquisition, segmentable structures, reference data, and professional review.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K260032
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-05-13
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-04Last searched
25Fields reviewed
11Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads

Screened 20 PubMed titles and 10 trial records. They are unrelated lexical matches for morph or clinical procedures and do not identify BeauBrain Morph or K260032; all 30 are quarantined. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, fda decision summary, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared product version was established. Obtain a written quote separating license, implementation, interfaces, compute, storage, training, support, upgrades, renewal, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The FDA decision material does not establish the complete security posture for the exact product and deployment. Obtain architecture, identity, audit, encryption, retention, support-access, vulnerability-management, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K260032: Morph

    U.S. Food and Drug Administration - Published 2026-05-13 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Morph model card (K260032)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K260032 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K261405

ANDI 2.2

Imeka Solutions, Inc.

Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.

Modality
MRI
Anatomy
Brain
Decision
2026-05-28
FDA-cleared K253057

AI-Rad Companion Brain MR

Siemens Healthcare GmbH

Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.

Modality
MRI
Anatomy
Brain
Decision
2026-01-22
FDA-cleared K252298

ANDI 2.0

Imeka Solutions, Inc.

Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.

Modality
MRI
Anatomy
Brain
Decision
2025-10-22
FDA-cleared K251483

SwiftSight-Brain

AIRS Medical Inc.

Authorized purpose: Adjunctive brain MRI morphometry and lesion-quantification support for qualified healthcare professionals, including segmented overlays, volumetric measurements, normative percentiles and longitudinal comparison.

Modality
MRI
Anatomy
Brain
Decision
2025-09-23

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history